Actinium Pharmaceuticals (ATNM) Leases (2021 - 2025)
Actinium Pharmaceuticals (ATNM) has disclosed Leases for 4 consecutive years, with $22000.0 as the latest value for Q3 2024.
- On a quarterly basis, Leases fell 99.1% to $22000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $22000.0, a 99.1% decrease, with the full-year FY2023 number at $2.3 million, up 76200.0% from a year prior.
- Leases was $22000.0 for Q3 2024 at Actinium Pharmaceuticals, down from $25000.0 in the prior quarter.
- In the past five years, Leases ranged from a high of $2.6 million in Q2 2023 to a low of $2000.0 in Q1 2023.
- A 4-year average of $544200.0 and a median of $58000.0 in 2021 define the central range for Leases.
- Peak YoY movement for Leases: surged 76200.0% in 2023, then plummeted 99.1% in 2024.
- Actinium Pharmaceuticals' Leases stood at $58000.0 in 2021, then crashed by 94.83% to $3000.0 in 2022, then soared by 76200.0% to $2.3 million in 2023, then tumbled by 99.04% to $22000.0 in 2024.
- Per Business Quant, the three most recent readings for ATNM's Leases are $22000.0 (Q3 2024), $25000.0 (Q2 2024), and $27000.0 (Q1 2024).